Business Context and Reporting Period
This Form 6-K filing by Evogene Ltd. covers the month of January 2023, with the report dated January 12, 2023. The filing discloses a material change in the management of Lavie Bio Ltd., a subsidiary of Evogene focused on ag-biological products for food quality and sustainability.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a disclosure of corporate governance changes and contains no financial statements or quantitative performance data.
Material Changes
- Executive Departure: Mr. Guri Oron, CEO of Lavie Bio, has requested to step down. He will remain in office through March 8, 2023, during the search for a replacement.
- Reason for Departure: The resignation is not the result of any disagreement with Evogene or Lavie Bio regarding operations, policies, or practices.
- Interim Leadership: Mr. Ofer Haviv, Evogene's President and CEO, will serve as the interim CEO of Lavie Bio until a permanent replacement is appointed.
Outlook, Risks, and Management Commentary
Management expressed gratitude to Mr. Oron for his services. The filing notes that the transition is being managed to ensure continuity while a search for a new CEO is conducted. No specific financial guidance, risk factors, or unusual items were disclosed in this document.
Key Facts for Investor Verification
- Confirm the timeline for the appointment of a permanent CEO for Lavie Bio following the March 8, 2023, interim deadline.
- Verify if the leadership change at Lavie Bio impacts ongoing product development or commercialization timelines.
- Review subsequent filings for any financial impact related to the executive transition.